Interesting comments from Dr. Yasmin. I was more
Post# of 72447
(Total Views: 833)
Posted On: 08/06/2020 7:49:43 PM
Interesting comments from Dr. Yasmin. I was more than happy with a 90% vs 50% viral reduction (80% improvement) in a somewhat apples to apples comparison but note Remdesivir used Vero cells. Brilacidin efficacy in human trials could be even greater than previously anticipated in comparison. IMO a good Selectivity Index will be announced soon which should be another proof point.
From 7/20/20 PR
Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus. The Brilacidin inhibition assay was tested in a human lung epithelial cell line, with Remdesivir™ tested in Vero cells. The RBL data also supports Brilacidin showing an ability to inhibit viral entry into cells, a highly desirable mechanism of action as it is the first step in the infection process enabling viruses to be targeted outside the cell, whereas Remdesivir™ impacts viral replication only after the host cell has been infected.
Dr. Seema Yasmin
@DoctorYasmin
Some scientists have been using the wrong cell lines to study SARS-CoV-2. Using the widely available Vero cells - instead of lung cells - is not helpful because while Vero cells are pretty convenient to work with, they have only 1 entry point for the virus (our lung cells have 2)
Dr. Seema Yasmin
@DoctorYasmin
·
6h
Replying to
@DoctorYasmin
This is how we ended up with some early botched findings about hydroxychloroquine. Hydroxychloroquine stops SARS-CoV-2 from infecting Vero cells - but it doesn't stop the virus from infecting human lung cells
From 7/20/20 PR
Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus. The Brilacidin inhibition assay was tested in a human lung epithelial cell line, with Remdesivir™ tested in Vero cells. The RBL data also supports Brilacidin showing an ability to inhibit viral entry into cells, a highly desirable mechanism of action as it is the first step in the infection process enabling viruses to be targeted outside the cell, whereas Remdesivir™ impacts viral replication only after the host cell has been infected.
Dr. Seema Yasmin
@DoctorYasmin
Some scientists have been using the wrong cell lines to study SARS-CoV-2. Using the widely available Vero cells - instead of lung cells - is not helpful because while Vero cells are pretty convenient to work with, they have only 1 entry point for the virus (our lung cells have 2)
Dr. Seema Yasmin
@DoctorYasmin
·
6h
Replying to
@DoctorYasmin
This is how we ended up with some early botched findings about hydroxychloroquine. Hydroxychloroquine stops SARS-CoV-2 from infecting Vero cells - but it doesn't stop the virus from infecting human lung cells
(12)
(0)